R

Rigel Pharmaceuticals
D

RIGL

21.830
USD
0.03
(0.14%)
مغلق
حجم التداول
6,255
الربح لكل سهم
1
العائد الربحي
-
P/E
81
حجم السوق
384,536,323
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AMGN
    AMGN
    -1.26
    (-0.46%)
    273.59 USD
    BMY
    BMY
    0.025
    (0.04%)
    57.075 USD
    GILD
    GILD
    0.070
    (0.08%)
    93.020 USD
    I
    INCY
    -1.050
    (-1.43%)
    72.420 USD
    LLY
    LLY
    11.37
    (1.53%)
    753.86 USD
    MRK
    MRK
    -0.560
    (-0.58%)
    95.670 USD
    PFE
    PFE
    -0.621
    (-2.33%)
    26.015 USD
    REGN
    REGN
    -7.47
    (-1.09%)
    679.85 USD
    المزيد
الأخبار
المقالات

العنوان: Rigel Pharmaceuticals Inc

القطاع: Healthcare
الصناعة: Biotechnology
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.